Molecular and clinical oncology最新文献

{"title":"New, safe and simple endoscopic cricopharyngeal myotomy with a curved rigid laryngoscope: A case report.","authors":"Takashi Maruo,&nbsp;Yasushi Fujimoto,&nbsp;Sayaka Yokoi,&nbsp;Mayu Shigeyama,&nbsp;Naoki Nishio,&nbsp;Mariko Hiramatsu,&nbsp;Michihiko Sone","doi":"10.3892/mco.2023.2606","DOIUrl":"https://doi.org/10.3892/mco.2023.2606","url":null,"abstract":"<p><p>Endoscopic cricopharyngeal myotomy (ECPM) is a safe and minimally invasive technique that is used to treat patients whose esophageal inlet fails to open because of specific diseases, such as Wallenberg's syndrome and neuromuscular diseases. The present study described the performance of a new, safe and simple ECPM using a curved rigid laryngoscope, which is used for endoscopic laryngopharyngeal surgery for patients with dysphagia due to pharyngeal residue after swallowing. The patient was an 80-year-old woman with laryngeal palsy caused by lower cranial nerve palsy after cranial base schwannoma surgery. ECPM was performed with a curved rigid laryngoscope. The postoperative course was good; postoperative rehabilitation eliminated the residue after swallowing a thickened solution and mealtimes were shorter than before surgery. This procedure allows the hypopharynx to be widely expanded and it is possible to develop a wider surgical field than when using a direct laryngoscope. In addition, this procedure appears to be relatively easy to perform if the surgeon is familiar with the curved rigid laryngoscope technique.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 2","pages":"10"},"PeriodicalIF":1.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/64/mco-18-02-02606.PMC9905648.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10688919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder tuberculosis with ureteral strictures after bacillus Calmette‑Guérin therapy for urinary bladder cancer: A case report.","authors":"Yusuke Tominaga,&nbsp;Masanori Fujii,&nbsp;Takuya Sadahira,&nbsp;Satoshi Katayama,&nbsp;Takehiro Iwata,&nbsp;Shingo Nishimura,&nbsp;Kensuke Bekku,&nbsp;Kohei Edamura,&nbsp;Tomoko Kobayashi,&nbsp;Yasuyuki Kobayashi,&nbsp;Katsuyuki Kiura,&nbsp;Yoshinobu Maeda,&nbsp;Koichiro Wada,&nbsp;Motoo Araki","doi":"10.3892/mco.2022.2603","DOIUrl":"https://doi.org/10.3892/mco.2022.2603","url":null,"abstract":"<p><p>Intravesical immunotherapy using bacillus Calmette-Guérin (BCG) is recommended for patients with intermediate- to high-risk non-muscle invasive bladder cancer. Bladder tuberculosis (TB) is a rare complication of BCG therapy. The present study describes the case of a 73-year-old man who underwent intravesical BCG therapy for urothelial carcinoma in situ of the bladder. Red patches around the resection scar were first detected 1 year and 5 months after BCG treatment; these findings gradually spread to encompass more of the bladder wall. Transurethral biopsy revealed a benign lesion, but the patient developed bilateral hydronephrosis and mild voiding dysfunction. The patient was eventually diagnosed with bladder TB by mycobacterial urine culture and TB-specific polymerase chain reaction (PCR). The patient was given multidrug therapy (isoniazid, rifampicin and ethambutol) and their bladder TB was completely cured; however, their voiding dysfunction and bilateral hydronephrosis did not fully improve. Bladder TB can occur long after intravesical BCG administration and cystoscopy findings consistent with inflammation can be the key to suspecting this condition. Acid-fast examination and PCR testing of a urine sample are necessary for early diagnosis.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 2","pages":"7"},"PeriodicalIF":1.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/8e/mco-18-02-02603.PMC9886853.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.","authors":"Morena Fasano,&nbsp;Mario Pirozzi,&nbsp;Vincenzo Famiglietti,&nbsp;Sergio Facchini,&nbsp;Marianna Caterino,&nbsp;Mara Caroprese,&nbsp;Angela Barillaro,&nbsp;Ilaria Di Giovanni,&nbsp;Annunziata Auriemma,&nbsp;Silvia Ileana Sara Fattoruso,&nbsp;Teresa Somma,&nbsp;Domenico Solari,&nbsp;Marco Bocchetti,&nbsp;Manuel Conson,&nbsp;Roberto Pacelli,&nbsp;Fortunato Ciardiello,&nbsp;Raffaele Addeo","doi":"10.3892/mco.2023.2605","DOIUrl":"https://doi.org/10.3892/mco.2023.2605","url":null,"abstract":"<p><p>Glioblastoma multiforme is one of the most frequent and aggressive primary tumors in the central nervous system, representing >60% of all brain tumors in adults. Despite treatment, prognosis remains poor with most if not all patients experiencing disease recurrence and a 2-year survival rate of 27%. At present, no confirmed standard treatment exists for recurrent glioblastoma. Regorafenib is one of the few options available, based on results from the REGOMA trial. In the present study, a real-life retrospective investigation on the role of regorafenib in patients with recurrent glioblastoma (>60 years old) from two main Oncological Units in South Italy (Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy and Ospedale Civile San Giovanni di Dio, Frattamaggiore, Naples, Italy), was performed. The primary endpoint was overall survival (OS), whereas progression-free survival (PFS), objective response rate and disease control were secondary endpoints. Survival was then analyzed according to age, isocitrate dehydrogenase (IDH) and methylated methylguanine-DNA-methyltransferase (MGMT) status. A total of 56 patients met the eligibility criteria. The intention to treat population median PFS (mPFS) was 4.1 months and median OS (mOS) was 6.8 months. Age did not appear to have a significant influence on mPFS. mOS in MGMT-methylated patients was improved compared with that of the unmethylated group (7.7 months vs. 5.6 months). Both mOS and mPFS were longer in IDH-mutant patients. The present study was one of the first real life analyses of regorafenib in recurrent glioblastoma. The results were in line with the REGOMA trial. Age did not appear to be a prognostic factor, thus suggesting that treatment choice should not be different in elderly. MGMT methylation appeared to influence OS. To the best of our knowledge, this was the first report of regorafenib activity in older patients and, while the results were statistically significant, these should be confirmed in further studies.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 2","pages":"9"},"PeriodicalIF":1.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/38/mco-18-02-02605.PMC9905649.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis.","authors":"Koshi Matsui,&nbsp;Mitsuharu Earashi,&nbsp;Akemi Yoshikawa,&nbsp;Wataru Fukushima,&nbsp;Zensei Nozaki,&nbsp;Kaeko Oyama,&nbsp;Kiichi Maeda,&nbsp;Akiyoshi Nakakura,&nbsp;Satoshi Morita,&nbsp;Tsutomu Fujii","doi":"10.3892/mco.2023.2608","DOIUrl":"https://doi.org/10.3892/mco.2023.2608","url":null,"abstract":"<p><p>Bevacizumab and eribulin are novel agents for the treatment of HER2-negative metastatic breast cancer (MBC); however, the choice between bevacizumab and eribulin for MBC can be difficult. The present study aimed to compare two treatment strategies, eribulin followed by bevacizumab and paclitaxel (BEV + PTX) versus BEV + PTX followed by eribulin, to determine whether the order of administration affects the outcome of MBC in the real world. A total of 180 patients who started BEV + PTX and eribulin treatment for HER2-negative MBC from August 2011 to June 2018 were selected. Of these, 84 patients were treated with both BEV + PTX and eribulin sequentially. To evaluate the influence of the sequential order, the efficacy of BEV + PTX followed by eribulin (B-E arm) was compared to treatment with the reverse sequence (E-B arm). The propensity score matching method (PSMA) was used to improve the robustness of the findings from the present study. A total of 60 cases analyzed received BEV + PTX or eribulin as either first- or second-line treatment. In the entire cohort, the median time to failure of strategy (TFS) was 16.8 and 9.9 months in the B-E and E-B arms, respectively [hazard ratio (HR)=0.515, 95% CI 0.298-0.889, P=0.017). A similar HR was derived from PSMA for TFS. Using PSMA, TFS was 16.9 and 9.9 months in the B-E and E-B arms, respectively (HR=0.491, 95% CI 0.253-0.952, P=0.031). These results suggested that when both bevacizumab and eribulin are administered, bevacizumab should be administered first and eribulin should be administered later to ensure the most effective use of each drug.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 2","pages":"12"},"PeriodicalIF":1.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/9a/mco-18-02-02608.PMC9892966.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential immune‑related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma.","authors":"Francesca Morgese,&nbsp;Valeria Cognigni,&nbsp;Laura Scortichini,&nbsp;Nicoletta Ranallo,&nbsp;Valentina Lunerti,&nbsp;Antonella Migliore,&nbsp;Francesca Tronconi,&nbsp;Rossana Berardi","doi":"10.3892/mco.2022.2598","DOIUrl":"https://doi.org/10.3892/mco.2022.2598","url":null,"abstract":"<p><p>In recent years, BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi), together with immune checkpoint inhibitors (ICIs), have changed the therapeutic strategy of cutaneous melanoma, both in adjuvant and metastatic settings. These inhibitors have significantly improved the clinical outcome for patients with melanoma, including in both BRAF-mutated and BRAF-wild type disease. Some preclinical and clinical studies have revealed that BRAFi and MEKi are able to influence T- and B-cell activation, and to modulate immune system activation within the tumor microenvironment. Dabrafenib and trametinib have been shown to enhance the expression of melanoma antigens on BRAF-mutated cells, and to favor both a cytotoxic and immune response against melanoma cells. Thereby, the present study described a case series of five women treated with BRAFi and MEKi, in both adjuvant and metastatic settings, that experienced potential immune-related adverse events. In particular, these patients exhibited sarcoidosis, mesenteric panniculitis, lymphocytic colitis and neuropathy of phrenic nerve. Considering that T and B cells are responsible for immune-related adverse events, as observed in patients treated with ICIs, the present study suggested a possible role of BRAFi and MEKi as triggers of immune system activation and subsequent immune-related toxicities.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"2"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756019/pdf/mco-18-01-02598.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10424575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of triple negative breast cancer gene expression profiles in Mexican patients.","authors":"Eric Ortiz Valdez,&nbsp;Claudia Rangel-Escareño,&nbsp;Juan Antonio Matus Santos,&nbsp;Rafael Vázquez Romo,&nbsp;Alberto Guijosa,&nbsp;Cynthia Villarreal-Garza,&nbsp;Oscar Arrieta,&nbsp;Rubén Rodríguez-Bautista,&nbsp;Claudia H Caro-Sánchez,&nbsp;Alette Ortega Gómez","doi":"10.3892/mco.2022.2601","DOIUrl":"https://doi.org/10.3892/mco.2022.2601","url":null,"abstract":"<p><p>Triple negative breast cancer (TNBC) is an aggressive type of cancer that accounts for ~23% of breast tumors in Mexico. In an attempt to understand in an improved way the behavior of TNBC, throughout the years, gene expression in these tumors has been studied. Lehman <i>et al</i> identified 6 subtypes of gene expression in TNBC with distinct characteristics. In the present study, it was aimed to assess clinical, pathological and prognostic characteristics of TNBC in a Mexican-based cohort. A total of 55 patients diagnosed with TNBC at Mexico's National Institute of Cancer (INCan) were included. Tumor needle biopsy samples were obtained and subjected to microarray analysis. Patients were thus classified into one of the 6 TNBC molecular subtypes. The prognostic, clinical and pathological information of patients was obtained, and differences across molecular subtypes were sought. Out of the 55 included patients, the following subtypes were identified: 9 basal-like-1, 11 basal-like-2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, 6 androgen receptor-like and 1 mesenchymal stem-like. Mean follow-up time was 47.1 months. The IM molecular subtype had the best overall survival (OS) (median OS was not reached). BSL2 had the worst OS (15 months). A complete pathologic response to neoadjuvant chemotherapy was obtained more often in the IM subtype (P=0.032). No significant associations were found between any of the clinical or pathological characteristics and the TNBC molecular subtypes. The results obtained from the present study should be considered when seeking to implement a clinical-molecular model for TNBC patient care, particularly in Hispanic-based populations, as they have been frequently underrepresented in clinical studies assessing TNBC molecular subtypes.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"5"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/56/mco-18-01-02601.PMC9808158.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10497987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of organ preservation treatment in advanced laryngeal carcinoma: A retrospective analysis from a single institution.","authors":"Afsar Fasaludeen,&nbsp;Rejnish Ravi Kumar,&nbsp;Malu Rafi,&nbsp;Farida Nazeer,&nbsp;Aparna Mullangath Prakasan,&nbsp;Naveen Kumar,&nbsp;Preethi George,&nbsp;Kunnambath Ramadas,&nbsp;Kainickal Cessal Thommachan","doi":"10.3892/mco.2022.2597","DOIUrl":"https://doi.org/10.3892/mco.2022.2597","url":null,"abstract":"<p><p>Chemoradiation is the standard treatment for patients with locally advanced laryngeal carcinoma with intact cartilage and functional larynx. The aim of this retrospective study was to assess overall survival (OS) and disease-free survival (DFS) of patients with locally advanced (stage III and stage IV) squamous cell carcinoma of the larynx who have been treated with definitive radical radiotherapy (RT) with or without chemotherapy in a tertiary cancer center in India between January 1, 2006 and December 31, 2015. Data were collected using structured proforma. The patients were treated with RT alone, induction chemotherapy (IC) followed by RT, concurrent chemoradiation therapy (CCRT) or IC followed by CCRT. Response assessment was conducted at 3-4 months post-treatment. Patient-, tumor- and treatment-related factors were documented and were associated with DFS and OS. Survival curves were generated using the Kaplan-Meier method and the statistical significance of survival curves was assessed using the log-rank test. Prognostic factors were assessed using the Cox proportional hazards regression model. A total of 630 patients were included in the present study. The most common age group at presentation was 50-70 years (n=477; 75.7%) and 95.4% (n=601) patients were male. The most common stage at presentation was stage III (n=367, 58.1%). The median follow-up period for the entire group of was 59 months (range, 2-175 months). A complete response after treatment was seen in 549 patients (87.1%). Salvage surgery was performed for 11 patients with residual disease. A total of 134 patients (21.3%) had developed locoregional and distant relapses, and salvage surgery was performed for 31 out of 102 patients with locoregional relapse. The 5-year OS was 48.7% and the 5-year DFS was 45.7%. The stage-wise OS rates were 58.9, 34.9 and 30.4% (P=0.001) and the stage-wise DFS rates were 56.3, 32.0 and 21.7 (P=0.001) for stage III, IVa and IVb, respectively. Results from the present study demonstrated the feasibility of delivery of chemoradiation protocols with good results in a developing country.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"1"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/b3/mco-18-01-02597.PMC9756020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10418915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of long non‑coding RNAs in renal cell carcinoma (Review).","authors":"Zhengming Su,&nbsp;Jian Ao,&nbsp;Fengjin Zhao,&nbsp;Guibin Xu,&nbsp;Huihua Chen,&nbsp;Chen Gao","doi":"10.3892/mco.2022.2600","DOIUrl":"https://doi.org/10.3892/mco.2022.2600","url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) are involved in the gene expression regulation and usually play important roles in various human cancers, including the renal cell carcinoma (RCC). Dysregulation of certain lncRNAs are associated with the prognosis of patients with RCC. In the present review, several recently studied lncRNAs were discussed and their critical roles in proliferation, migration, invasion, apoptosis and drug resistance of renal cancer cells were revealed. The research on lncRNAs further increases our understanding on the development and progression of RCC. It is suggested that lncRNAs can be used as biomarkers or therapeutic targets for diagnosis or treatment of renal cancer.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"4"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780631/pdf/mco-18-01-02600.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10468907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population‑based prostate‑specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan.","authors":"Susumu Kageyama,&nbsp;Yuki Okinaka,&nbsp;Koji Nishizawa,&nbsp;Toru Yoshida,&nbsp;Satoshi Ishitoya,&nbsp;Yasumasa Shichiri,&nbsp;Chul Jang Kim,&nbsp;Tsuyoshi Iwata,&nbsp;Ryusei Yokokawa,&nbsp;Yutaka Arai,&nbsp;Zenkai Nishikawa,&nbsp;Hiroki Soga,&nbsp;Hiroshi Ushida,&nbsp;Yuji Sakano,&nbsp;Yoshio Naya,&nbsp;Akinori Wada,&nbsp;Masayuki Nagasawa,&nbsp;Tetsuya Yoshida,&nbsp;Mitsuhiro Narita,&nbsp;Akihiro Kawauchi","doi":"10.3892/mco.2022.2599","DOIUrl":"https://doi.org/10.3892/mco.2022.2599","url":null,"abstract":"<p><p>Prostate cancer is the most common genitourinary cancer in men. Population-based serum prostate-specific antigen (PSA) testing is used to screen men for the early detection of asymptomatic prostate cancer. The present study compared the features of patients with prostate cancer in Kusatsu City, the only municipality in Shiga Prefecture of Japan to implement organized PSA screening, with those in other municipalities. The target population for organized PSA screening by mail invitation was men ≥50 years. Patients were pathologically diagnosed via prostate biopsy because of elevated serum PSA. This multicenter observational study was subsequently conducted in 14 hospitals. The following information was extracted from patient records: age, reason for PSA testing, initial PSA level, Gleason score, clinical stage, and place of residence. Risk classification was defined as low, intermediate, high, and advanced. Each patient was stratified according to their city/town. A total of 984 patients diagnosed with prostate cancer in Shiga in 2012 and 2017 were analyzed, of which 955 (97%) were opportunistically tested, with the remaining 29 (3%) assessed by organized screening. In Kusatsu, 93 patients were diagnosed, of whom 26 (28%) were detected by organized screening. By contrast, only three of 891 patients (0.3%) were detected by organized screening in other municipalities. Of patients in Kusatsu, cases identified by opportunistic testing had a higher initial PSA value (P=0.010) than those identified by organized screening. However, patients detected through opportunistic testing in Kusatsu City were younger (P=0.034), had a lower PSA value (P=0.001), and improved risk classification (P<0.001) than those in other municipalities. It was concluded that more patients were diagnosed with early-stage cancer by organized PSA screening. Furthermore, population-based PSA screening in Kusatsu City may have indirectly affected early detection, even by opportunistic testing.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"3"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/d3/mco-18-01-02599.PMC9756018.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10418919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of thoracic multidisciplinary tumor boards on the management of patients with cancer: A retrospective study at the American university of Beirut medical center.","authors":"Firas Kreidieh,&nbsp;Arafat Tfayli","doi":"10.3892/mco.2022.2602","DOIUrl":"https://doi.org/10.3892/mco.2022.2602","url":null,"abstract":"<p><p>Multidisciplinary tumor boards (MDT) provide an opportunity for experts from different specialties and expertise to pool and complement each other's experience and inputs. Several factors impact the MDT discussions, including the meeting's structure, time management, and expert leadership. The process of MDT, their utilization, and efficacy need continuous assessment and improvement. A retrospective study was conducted to review the process of thoracic MDT, their plans of therapy, and changes in diagnosis and treatment plans for patients with cancer at the American University of Beirut Medical Center (AUBMC) over the period of one year. The primary outcome measure was the percentage of patients presented at the thoracic MDT who had a change in their treatment plan after the presentation. A total of 214 cases were scheduled for thoracic MDT during the study period. The majority, 132 (61.7%) did not have a treatment plan before presenting in the MDT. Of the 195 cases presented, only 43 (22.0%) did not have a change in their plan, while 88 (45.2%) of the cases presented had a change in their treatment plan. A total of 64 (32.8%) cases consisted of discussion of the diagnosis during MDT with either confirmation or modification of the patients' diagnosis. Of the 195 cases that were presented, the majority, 170 (87.2%), had their recommended treatment plan implemented after the MDT discussion. There was an association between the stage of cancer at the time of presentation and requesting additional tests (P=0.021), but there was no association between the stage of cancer and change in treatment plan (P=0.177) nor with implementation of recommendation (P=0.217). MDT are used to make upfront management decisions. In addition to considering change in management plans as an indicator of the benefit of MDT, it is suggested that making upfront multidisciplinary plans shall be considered an additional component of indicators of the benefit of MDT.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 1","pages":"6"},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808157/pdf/mco-18-01-02602.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10497989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}